JDP Therapeutics, Inc.

Here's your news in brief: The US FDA’s Center for Biologics Evaluation and Research approved its first novel therapy in 2019 with the clearance of Novo Nordisk AS ’s long-acting coagulation Factor V

With data from a positive Phase II study in hand, Novartis AG says it will now compare its investigational anti-IgE antibody, ligelizumab (QGE031) with its marketed anti-IgE MAb, Xolair (omalizuma

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

Aiming to improve treatment of acute allergic reactions 823 Jays Drive Lansdale, PA 19446 Phone: (215) 661-8557 Web Site: www.jdptherapeutics.com Contact: Jie Du, PhD, President & CEO Industry Segme